BioAlliance Pharma announces the execution of its licensing agreement with Vestiq Pharmaceuticals for Oravig® in the US

Paris, September 24, 2012 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig® in the United States (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis in adults.

Under this agreement, BioAlliance Pharma should receive up to $44 million from Vestiq, the first $9 million corresponding to unconditionnal payments to be spread over 24 months. The agreement also includes significant royalties on sales. Vestiq will become the Marketing Authorization Holder of the product and will assume all related responsibilities.

At this stage, BioAlliance Pharma and Vestiq are actively preparing the US launch of Oravig® that should occur within the next few months.

« This agreement with Vestiq should allow the development of Oravig®'s US commercial potential and ensure its success in the top global market, driven by a skilled and experienced team in the promotion of Specialty pharma products", declares Judith Greciet, CEO of BioAlliance Pharma.

"It is with great enthusiasm that we are initiating this collaboration with BioAlliance Pharma. Oravig® will become a key pharmaceutical product in our portfolio. It perfectly fits with Vestiq's development strategy in the area of oncology supportive care", declares Martin Baum, CEO of Vestiq Pharmaceuticals.

About Vestiq Pharmaceuticals

Based in North Carolina, Vestiq is a privately held company specialized in the promotion of oncology supportive care products. Vestiq has been founded by highly experienced pharmaceutical executives with a successful track record in building specialty pharma companies.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's

teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)
Sitavir®/Sitavig® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status
Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Oncology Orphan products
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going
Validive® (Clonidine Lauriad™) (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2011 Reference Document filed with the AMF on April 24, 2012, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
Christian Berg
Tel: +33 1 42 68 86 41
christian@alizerp.com